Phase I Dose-Escalation Clinical Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Patients with Low-risk Hormone Receptor-positive and Her2-negative Breast Cancer Not Suitable or Who Refuse Surgery: DESERT I Trial

Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery. However, in recent years, there has been research into the potential benefit of administering RT prior to surgery in a neoadjuvant manner. Given that these studies have shown promising results, it is logical to think that certain patients could benefit from exclusive RT treatment, thereby avoiding surgery and its possible sequelae. This study is a phase I dose-escalation clinical trial with sequential assignment, open-label, in which five different doses (20Gy, 23Gy, 26Gy, 28Gy, and 30Gy) will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique.
The aim of the study is to determine the maximum tolerated dose (MTD) based on acute toxicity, which will allow us to proceed with a phase II clinical trial to confirm efficacy and assess the late toxicity of the treatment. Secondary objectives include assessing the pathological response via core needle biopsy (CNB), radiological response, quality of life, and cosmesis. Additionally, molecular studies will be conducted on tissue and through liquid biopsy; pre- and post-treatment, we aim to identify mutations and predictors of response.

开始日期2024-09-27

申办/合作机构

Universitat De Les Illes Balears

NCT04012476

/ Unknown status临床4期IIT

Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy

The intensity of parathyroid fluorescence that occurs after intravenous injection of indocyanine green during the performance of a total thyroidectomy correlates with postoperative parathyroid function and could be used as a diagnostic marker of postoperative hypoparathyroidism and hypocalcemia.

开始日期2016-11-01

申办/合作机构

Universitat De Les Illes Balears

ISRCTN76069254

/ CompletedN/AIIT

To evaluate the effectiveness of a brief multifactorial intervention designed to improve the adherence to physical exercise prescription of moderate to high cardiovascular risk patients

开始日期2015-01-01

申办/合作机构

Universitat De Les Illes Balears

100 项与 Universitat De Les Illes Balears 相关的临床结果

登录后查看更多信息

0 项与 Universitat De Les Illes Balears 相关的专利（医药）

登录后查看更多信息

3,157

项与 Universitat De Les Illes Balears 相关的文献（医药）

2025-08-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Advancing green and white assessment: DFT-assisted spectrofluorimetry for accurate favipiravir quantification in human plasma

Article

作者: Frontera, Antonio ; Obaydo, Reem H ; Ali, Marwa F B ; Hosny, Noha M

Recently, the recognition of computational chemistry potential is growing, because of its applicability for design of substances and studying their properties using computer programs and modelling approaches that help solve various problems. Computational chemistry is involved in the design of advanced fluorescent probes which can be employed in sensing of various analytes. Favipiravir (FVR) is an antiviral drug recommended for the treatment of COVID-19, known for its broad-spectrum activity against RNA viruses by inhibiting viral RNA-dependent RNA polymerase. This study introduces the first-ever integration of computational density functional theory (DFT) and experimental spectrofluorimetric approach to design a highly sensitive spectrofluorimetric method for estimation of FVR in its bulk form and human plasma. The DFT analysis was carried out to investigate the affinity of Zirconium (Zr⁴⁺) to FVR in aqueous solution and explore the formation of FVR-Zr⁴⁺ chelate. The combuted formation energy (ΔG = -416.5 kcal/mol) of [Zr (FVR)₄]⁴⁺ complex confirmed the strong of ability of Zr⁴⁺ to recognize FVR in solution and evidenced the strong nature of the Zr⁴⁺- O and N coordination bonds. The results revealed a significant enhancement in the weak native fluorescence of FVR upon formation of the complex. Various experimental parameters were examined, further the established method was validated according to ICH standards where linearity range was achieved in the range of 0.50-200.0 ng mL^-1, with low detection limit reached 32.99 pg mL^-1. The developed DFT-assisted spectrofluorimetric methodology was successfully employed for FVR assessment in human plasma samples with good recoveries (98.74 -100.10 %) and relative standard deviation did not exceed 1.80 %. Moreover, the proposed method's eco-friendliness and sustainability were evaluated through four metrics (Red/Green/Blue 12 Algorithm (RGB12), Green Solvent Selection Tool (GSST), Analytical Greenness Metric (AGREE), and Analytical Greenness Metric for Sample Preparation (AGREEprep)), demonstrating its superiority over the existing methods in terms of using safer solvents, reduced sample preparation procedures, and higher overall greenness. Additionally, the high sensitivity and applicability of the proposed method to the reliable analysis of both bulk drug and plasma samples make it efficient and practical for routine FVR analysis in both pharmaceutical and clinical settings. Furthermore, this study opens new avenues for extending computational and experimental approaches to analyze FVR in real samples and explore other drug-metal interactions, contributing to advancements in drug analysis and mechanistic studies.

2025-08-01·Separation and Purification Technology

MIL-100(Fe)@PES composite polymer beads for adsorption and preconcentration of pharmaceuticals in water samples

作者: Palomino Cabello, C. ; Turnes Palomino, G. ; Castro-Garcia, C. ; del Rio, M.

In this study, we developed MOF@polymer composite beads by incorporating MIL-100(Fe) into polyethersulfone (PES) for the adsorption and preconcentration of pharmaceuticals from water.By varying the MOF/polymer ratio, composites with high porosity and surface areas up to 716 m² g^-1 were obtained, whose adsorption performance improved with increasing MOF content.The optimized MIL-100(Fe)@PES composite exhibited a maximum adsorption capacity of 109 mg g^-1 for diclofenac (DCF), with equilibrium reached in 6 h.Adsorption followed a Langmuir model, suggesting monolayer coverage, and was driven by hydrogen bonding between DCF and MIL-100(Fe).The composite demonstrated excellent reusability, maintaining adsorption efficiency over three consecutive cycles with a relative standard deviation of 0.5 %.By packing the compound on a flow-through solid phase extraction (SPE) HPLC column, limits of detection and quantification of 1.2 and 4.0 μg L-¹ were achieved for DCF, with intra- and inter-day precision below 6.7 %.The extraction efficiency increased with composite mass up to 1.0 g and was optimized at a flow rate of 1.0 mL min^-1.Finally, the MIL-100(Fe)@PES beads were tested for the extraction and preconcentration of diclofenac and ibuprofen from groundwater, achieving enrichment factors of 6 and 4, resp., with no significant matrix effects.

2025-06-01·Medicina Clínica

Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?

Article

作者: Nadal, Cristina ; Tamayo, María Isabel ; Nadal, Antoni ; Pujol, Antelm ; Masmiquel, Lluís ; Sanchís, Pilar ; Nicolau, Joana

INTRODUCTIONObesity and psoriasis are two closely related chronic diseases and share multiple comorbidities. The common etiopathogenic basis would be a low-grade chronic inflammation, with a cross talk between adipose tissue and the skin. Obesity in patients with psoriasis results in a worse prognosis of the lesions and reduces the effectiveness of treatment.OBJECTIVESTo assess the mid-term effect of liraglutide 3mg on anthropometric and morphofunctional, biochemical, and dermatological parameters in patients with psoriasis and obesity.MATERIAL AND METHODS48 patients were included (52.1%♀, age 48.7±11.8 years, BMI 37.9±5.6kg/m², psoriasis duration 17.8±11.1 years). The severity of the lesions was evaluated with the PASI (Psoriasis Area Severity Index) and the VAS (pain visual analog scale), and DLQI (Dermatology Quality Index) and the Beck depression test (BDI). Also, biochemical and anthropometric determinations were performed baseline and after 6 months.RESULTSThere was a reduction in BMI (37.9±5.6 vs 35±4.9; p<0.001), waist circumference (111.6±7 vs 104.7±9.3cm; p=0.001) and preperitoneal fat (1.6±0.6 vs 1.2±0.6cm; p<0.0001). PASI (12±8.4 to 4.3±2.9; p<0.0001), VAS (4.4±1.9 vs 2.2±1.6; p=0.003), DLQI (11.9±6.2 vs 4.8±3.4; p<0.0001) and BDI (15.5±3.6 vs 7.6±2.5; p<0.0001) improved significantly. C-reactive protein (3.9±3.1 vs 1.8±3.2mg/L; p<0.0001), homocysteine (13±3.3 vs 9.6±2.5μmol/L; p<0.0001), and plasma cortisol (12.5±4 vs 8.9±3.7μg/dL; p=0.001). In multiple regression analysis, dermatological improvement was independent of weight loss.CONCLUSIONSLiraglutide exerts beneficial effects not only on BMI and visceral fat, but also reduces inflammatory parameters in patients with psoriasis and obesity, improving skin lesions and quality of life.

项与 Universitat De Les Illes Balears 相关的新闻（医药）

2016-12-12

·laminarpharma.com

Dr Rosselló awarded a Felip Bauçà grant - laminarpharma

Palma de Mallorca (Spain), December 12th 2016 – The postdoctoral researcher Catalina Ana Rosselló Castillo has been awarded a Felip Bauçà fellowship at the CAIB (Comunitat Autònoma de les Illes Balears) Postdoctoral call from the 17th of June of 2016 to carry out the project “Desarrollo del nuevo fármaco antitumoral LP226: mecanismo molecular subyacente a su efecto antitumoral y antimetastático” at Laminar Pharma Therapeutics SL. Felip Bauçà is a highly competitive programme that awards 2-year fellowships for investigators with postdoctoral experience outside the Comunitat Autònoma de les Illes Balears. Dra. Rosselló obtained the only position opened in 2016 that was awarded on the 29th of November 2016. Catalina Ana Rosselló has an outstanding CV. She graduated in Biology as well as Biochemistry at the Universitat de les Illes Balears (UIB). She did her PhD at the Universidad Autónoma de Madrid, studying the role of Meis1 in hematopoietic stem cells, obtaining the best marks, and she has worked as a postdoctoral fellow for over 3 years at Lunds Universitet (Sweden) specialising in deregulation of cell cycle in cancer. In 2014, she was the first and only to date to be awarded a Marie Curie Intra-European Fellow from the 7th Framework Programme of the European Commission to join the Universitat de les Illes Balears as experienced researcher. She is an expert in the use of vertebrate laboratory animal models, histological techniques, genome-wide analysis techniques and cell culture. We, at Laminar Pharma Therapeutics SL, are very pleased to welcome Dr Rosselló on board of our team and wish her a big success.

高管变更

100 项与 Universitat De Les Illes Balears 相关的药物交易

登录后查看更多信息

100 项与 Universitat De Les Illes Balears 相关的转化医学

登录后查看更多信息